Search clinical trials for: LCZ696

Total 79 results

Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction (PARALLEL-HF)

Heart Failure With Reduced Ejection Fraction (HF-rEF)

Japan
Advanced Accelerator Applications

Recruiting

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake (NeoRay)

Neoplasms

United States, Netherlands, Austria, Spain, France, Germany, United Kingdom
Novartis Pharmaceuticals

Completed

COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure (CONFIDENCE-HF)

Heart Failure | Erectile Dysfunction | Heart Failure, Systolic

Germany
Novartis Pharmaceuticals

Recruiting

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Hypertension

Japan
Novartis Pharmaceuticals

Completed

CLCZ696B2319E1 OL Extension Study to Evaluate Long-term Safety of Sacubitril/Valsartan in Pediatric Patients With HF

Heart Failure

United States, Italy, Croatia, India, Japan, Poland, Spain, Taiwan, Austria, Korea, Republic of, Germany, Lebanon, Thailand, Canada, Bulgaria, Russian Federation, Turkey, Switzerland, Argentina, Hungary, Portugal, Finland, South Africa and more
Vanderbilt University Medical Center

Active, not recruiting

Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1

Hypertension

United States
University of Nebraska
National Cancer Institute (NCI); Genta Incorporated

Terminated

Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma

Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Diffuse Large Cell Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma | Stage I Adult Diffuse Large Cell Lymphoma

United States
Novartis Pharmaceuticals

Terminated

An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.

Heart Failure With Preserved Ejection Fraction (HFpEF)

Japan
Mark Ledwidge
The Heartbeat Trust

Active, not recruiting

Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation (PARABLE)

Hypertension | Atrial Remodeling | Cardiovascular Morbidity | Myocardial Dysfunction | Atrial Arrhythmia | Left Ventricular Remodeling | Left Ventricular Diastolic Dysfunction | Inflammatory Myopathy | Fibrosis Myocardial

Ireland
Novartis Pharmaceuticals

Completed

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event (TRANSITION)

Heart Failure With Reduced Ejection Fraction

Italy, Czechia, Russian Federation, Saudi Arabia, Turkey, Belgium, Switzerland, United Kingdom, Spain, Canada, Lebanon, Germany, Slovakia, Portugal, France, Poland, Argentina, Norway, Sweden
Novartis Pharmaceuticals

Completed

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode. (PIONEER-HF)

Acute Heart Failure

United States
Asan Medical Center
Novartis

Completed

Pharmacological Reduction of Functional, Ischemic Mitral REgurgitation (PRIME)

Mitral Valve Insufficiency | Left Ventricular Dysfunction

Korea, Republic of
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan

Hypertension

United States, Spain, Philippines, Guatemala, Russian Federation, Argentina, Puerto Rico
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine

Essential Hypertension

Taiwan, Japan, Philippines, China, Korea, Republic of, Malaysia
Novartis Pharmaceuticals

Completed

Pharmacokinetics of LCZ696 in Subjects With Mild and Moderate Renal Impairment Compared to Healthy Subjects With Normal Renal Function

Mild and Moderate Renal Impairment

Russian Federation, Germany, Serbia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Essential Hypertension

Japan
Novartis Pharmaceuticals

Completed

Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

Hypertension With Renal Dysfunction

Japan
Novartis Pharmaceuticals

Completed

A Study of LCZ696 in Subjects With Mild and Moderate Hepatic Impairment Compared With Normal Healthy Volunteers

Hepatic Impairment

Germany
National Medical Research Center for Cardiology...
Ministry of Health of Russian Federation

Recruiting

LCZ696 in Advanced LV Hypertrophy and HFpEF

Heart Failure | Essential Hypertension

Russian Federation
Mohammed Alnims

Completed

Six Months Clinical and Echocardiographic Outcome of ARNI LCZ696 Therapy in HFrEF Patients

Heart Failure With Reduced Ejection Fraction

Egypt
The Second Affiliated Hospital of Harbin Medical...

Unknown

Observation on the Effect of Sacubitril/Valsartan in Advanced Chronic Kidney Disease（CKD）Patients With Heart Failure

CKD
LanZhou University

Recruiting

Effect of LCZ696 on Urinary Microalbumin and Pulse Wave Velocity in Perimenopausal Patients With Hypertension

Hypertension

China
Novartis Pharmaceuticals

Completed

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

Heart Failure With Preserved Ejection Fraction (HFpEF)

United States, Canada
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction (PERSPECTIVE)

Chronic Heart Failure (CHF)

Spain, Croatia, Taiwan, Germany, Italy, United States, Australia, Netherlands, Switzerland, Belgium, United Kingdom, Bulgaria, Lithuania, Russian Federation, France, Argentina, Korea, Republic of, Poland, Canada, Turkey
Duke University
National Heart, Lung, and Blood Institute (NHLBI)

Completed

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study) (HFN-LIFE)

Heart Failure

United States
Novartis Pharmaceuticals

Withdrawn

Open-label Extension Study for CLCZ696G2301 (PARADISE-MI)

Post Myocardial Infarction
Novartis Pharmaceuticals

Completed

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction (EVALUATE-HF)

Heart Failure and Reduced Ejection Fraction

United States
Novartis Pharmaceuticals

Completed

Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure

Heart Failure

Russian Federation
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction (PARAGON-HF)

Heart Failure With Preserved Ejection Fraction

China, Germany, United States, Colombia, South Africa, Italy, Austria, Belgium, Croatia, Romania, Taiwan, Japan, Netherlands, Denmark, France, Israel, Spain, Switzerland, Korea, Republic of, Argentina, Canada, United Kingdom, Bulgaria, Gree... and more
Novartis Pharmaceuticals

Completed

randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure (OUTSTEP-HF)

Chronic Heart Failure With Reduced Ejection Fraction

Belgium, Estonia, Denmark, Greece, United Kingdom, Germany, Latvia, Lithuania, Spain, Netherlands, Bulgaria, Finland, Poland, Czechia, Iceland, Sweden, France, Ireland, Norway
Centre Hospitalier de PAU
University Hospital, Bordeaux

Completed

Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE)

Nervous System Diseases | Multiple Sclerosis, Chronic Progressive

France
Brigham and Women's Hospital
Novartis Pharmaceuticals

Withdrawn

Comparing ARNI With ACE Inhibitor on Endothelial Function (PARADOR)

Heart Failure With Reduced Ejection Fraction
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension

Essential Hypertension

China, Korea, Republic of, Taiwan, Hong Kong, Thailand, Philippines, Singapore
Novartis Pharmaceuticals

Completed

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

Hypertension

United States, Colombia, Spain, Germany, Taiwan, Russian Federation, Argentina, France, Italy, Korea, Republic of, Japan, Greece
Novartis Pharmaceuticals

Completed

Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers

Hypertension

Russian Federation
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Essential Hypertension

Taiwan, Japan, Hong Kong, Thailand, Philippines, China, Korea, Republic of
Procter and Gamble

Completed

Evaluation of the Anticaries Efficacy of Dentifrice Formulations Using an In-situ Model

Caries

Australia
Novartis Pharmaceuticals

Completed

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

Cardiomyopathy, Hypertrophic

United States, Germany, United Kingdom, Spain, Korea, Republic of, Greece
Duke University
Novartis Pharmaceuticals

Completed

Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019 (PARACOR-19)

Covid19

United States
Novartis Pharmaceuticals

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week, Double-blind Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure

Pediatric Heart Failure

United States, Italy, Croatia, Japan, Saudi Arabia, Spain, Austria, Korea, Republic of, Germany, Thailand, Canada, Bulgaria, India, Russian Federation, Turkey, France, Switzerland, China, Taiwan, Lebanon, Poland, Argentina, Hungary, P... and more
Novartis Pharmaceuticals

Completed

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Chronic Heart Failure With Reduced Ejection Fraction

Germany
Novartis Pharmaceuticals

No longer available

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

Heart Failure With Reduced Ejection Fraction (HF-rEF)

Germany, Spain, France, Greece, Lebanon, Austria, Ireland, Slovenia, Australia, Philippines, Brazil, Panama, United States, Croatia, Cyprus, Malta, Switzerland, United Arab Emirates
Jiangsu Cancer Institute & Hospital

Unknown

A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

Diffuse Large B-Cell Lymphoma (DLBCL)

China
University of Sao Paulo General Hospital

Completed

The Effect of Neprilysin (LCZ696) on Exercise Tolerance in Patients With Heart Failure (NEPRIExTol)

Heart Failure | Body Composition | Vasodilation | Muscle Strength | Exercise Tolerance

Brazil
Minneapolis Heart Institute Foundation
Abbott Medical Devices

Completed

Corticosteroid Pulse After Ablation (SAAB)

Atrial Fibrillation

United States
Novartis Pharmaceuticals

Completed

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Chronic Heart Failure With Reduced Ejection Fraction

India, Romania, Belgium, Czechia, Estonia, Hungary, Russian Federation, Taiwan, United Kingdom, Spain, Israel, Thailand, Canada, Korea, Republic of, United States, Bulgaria, Denmark, Netherlands, Philippines, Lithuania, Germany, T... and more
Merck Sharp & Dohme LLC

Completed

Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)

Diabetes Mellitus, Type II
Novartis Pharmaceuticals

Completed

Efficacy and Safety of LCZ696 Compared to Placebo in Patients With Essential Hypertension

Hypertension

China, Taiwan, Japan, Thailand, Korea, Republic of
Novartis Pharmaceuticals

Completed

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

Systolic Hypertension

United States, Spain, Hungary, Korea, Republic of, Argentina, India, Slovakia, Canada, Romania
Novartis Pharmaceuticals

Completed

A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension

Essential Hypertension

China, Taiwan, Japan, Thailand, Korea, Republic of

Search clinical trials for: LCZ696

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Pakistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations